Introduction
Alzheimer's disease (AD) is the most common cause of dementia and represents a growing burden for aging societies. 1 In 2006, 26.6 million people were estimated to be affected worldwide by this neurodegenerative disease and projection forecasts the number of AD patients to rise to over 100 million in 2050. 2 According to the amyloid cascade hypothesis, 3, 4 accumulation and aggregation of amyloid β-peptides (Aβ-peptides) in the brain plays a crucial role in the development and progression of AD. Aβ-peptides are produced by sequential proteolytic cleavages of the amyloid precursor protein (APP) executed by two membrane-associated enzymes called β-and γ-secretase. The transmembrane protein aspartyl protease β-site APP cleaving enzyme 1 (BACE1) (also called Asp2 or memapsin2) was discovered and cloned by several groups in 1999. [5] [6] [7] [8] [9] Subsequently, BACE1 was shown to represent the primary β-secretase activity in cultured cells and in vivo.
10 BACE1 cleaves APP in the lumenal/ extracellular region to release a soluble, extracellular N-terminal fragment (sAPPβ). 11 The residual membrane-tethered C-terminal fragment C99 is subsequently cleaved by γ-secretase to generate different Aβ-peptides and the APP intracellular domain (AICD). BACE1 represents a potential therapeutic target for reducing the formation of Aβ-peptides. Several BACE1 inhibitors have been reported. 12 -15 BACE1 appears to have diverse substrates and important physiological functions. Therefore, very careful dosing of BACE1-inhibiting drugs may be required to minimise possible adverse side effects. 10 Mature BACE1 cycles between the plasma membrane, the endosomal compartment and the trans-Golgi network. The proteolytic activity of BACE1 on wild-type APP appears to be mainly confined to the endocytotic pathway 16, 17 and can be increased by stimulating BACE1 internalisation. 18 Therefore, an efficient BACE1 inhibitor should be either membrane-permeable or targeted to the membrane to become available in the endosomes. Lipid rafts, liquid-ordered membrane domains enriched in cholesterol and sphingolipids, 19, 20 appear to be important for BACE1 cleavage of APP. BACE1 has been detected in lipid raft fractions 21 and reduction of cholesterol was shown to decrease cellular Aβ-production. 22, 23 In order to achieve high local concentrations of BACE1 inhibitors in designated subcellular regions, 16 we have reported the "tripartite structure" concept in 2005. 24 Tripartite structures are assembled by covalent coupling of BACE1 inhibitors with membrane anchors via suitable spacers. The spacer is designed to keep the inhibitor at an appropriate distance from the plasma membrane. The membrane anchor should bind the tripartite structure preferentially to the lipid raft domains of the membrane. Thus, an enrichment of the tripartite structure in the lipid rafts is achieved with "raftophilic" membrane anchors (Fig. 1) .
Tripartite structures are rapidly internalised by endocytosis and inhibit BACE1 much more efficiently than the corresponding free inhibitors in cell lines and primary neuronal cell culture. 25, 26 Moreover, they were reported to be active in vivo when injected stereotactically into the hippocampus of transgenic APPsw/PSΔ9 mice. 25 Herein, we describe the synthesis of novel tripartite structures and extensive studies regarding their structure-activity relations (SAR) in cell-based assays. In continuation of our previous work, [24] [25] [26] we report in detail the effect of different lipophilic membrane anchors and spacers on the activity of tripartite structures carrying the prototype peptidic pharmacophore GL189. Furthermore, we show that the potency of different non-peptidic transition state BACE1 inhibitors is substantially improved by incorporation into our tripartite structures.
Results and discussion
Tripartite structures were assembled from preformed building blocks by solid-phase peptide synthesis. The building blocks, used as pharmacophores, spacers and lipid anchors, were either obtained commercially or synthesised as described below. For a detailed SAR study by variation of lipid anchor and spacer modules, we used the same peptidic substrate-based inhibitor as before (GL189 = H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-NH 2 ). 27 Modifications of further literature-known BACE1 inhibitors, obtained by de novo synthesis, provided additional building blocks for solid-phase peptide synthesis.
The membrane anchor building blocks were obtained by esterification of lipidic alcohols, e.g. dihydrocholesterol (Dhc-OH) with the protected amino acid Fmoc-Asp-OtBu (1) using 1-(2-mesitylensulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) or N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC·HCl) (Scheme 1). Cleavage of the tert-butyl esters 2a-j with trifluoroacetic acid afforded the Fmoc-protected building blocks 3a-j, suitable for solid-phase peptide synthesis.
Ideally, the inhibitor should be positioned by the spacer close to the active site of BACE1 by keeping a similar distance from the plasma membrane. Moreover, the spacer should not affect the interaction between BACE1 and the inhibitor. We have chosen oligoethylene glycol units as spacer modules due to their low toxicity, high bio-compatibility, high stability and good solubility under physiological conditions. To investigate the potential influence of the chemical composition of spacer modules, the aminomethylphenylacetic acids 5a and 5b were tested as alternative building blocks. Using the commercially available N-Fmoc-ω-amino(oligoethylene glycol)carboxylic acids 4a-g or the N-Fmoc-aminomethylphenylacetic acids 5a and 5b as buildingblocks, spacers of various lengths were prepared. The N-Fmocprotected carboxylic acids were directly suitable for solid-phase peptide synthesis (Fig. 2) .
The tripartite structures were prepared by automated solidphase peptide synthesis and purified by preparative HPLC (see the Experimental section). The structures were supported by mass spectrometry. Previous advanced NMR experiments confirmed that the peptide synthesis proceeded without epimerisation and single diastereoisomers were obtained. 26 According to HPLC analysis, the purities of tripartite structures generally were higher than 99.9% (Table 1) .
As described previously, the biological activity of the tripartite structures was determined by measuring the concentration of Aβ40 peptides secreted by cultured SH-SY5Y cells overexpressing human wild-type APP695. 26 
Variation of the membrane anchor
The affinity of membrane anchors to lipid rafts depends on their structural features. Therefore, we have studied the effect of different membrane anchors on the efficiency of tripartite structures as BACE1 inhibitors in a cellular assay. Assuming that amyloidogenic APP cleavage by BACE1 is dependent on lipid 1 Tripartite structure concept. Anchoring of the pharmacophore (BACE1 inhibitor) via an appropriate spacer to a raftophilic membrane anchor leads to an increase of the inhibitor concentration in the proximity of the active site of BACE1 as both are located in the lipid rafts.
Scheme 1 Synthesis of membrane anchor building blocks 3a-j. Reagents and conditions: (a) 1.1 equiv. Fmoc-Asp-OtBu (1), 1.0 equiv. Dhc-OH (or Chol-OH, C n H 2n+1 OH (n = 14, 16, 18, 20, 22, 24, 26) or oleyl-OH), 1.1 equiv. MSNT and 1.1 equiv. MeIm (or 1.5 equiv. EDC·HCl cat. DMAP), CH 2 Cl 2 , rt, 4-52 h; (b) CF 3 COOH, CH 2 Cl 2 (1 : 0.8-1.5), rt, 90 min, 3a: 71%, 3b: 61%, 3c: 67%, 3d: 64%, 3e: 76%, 3f: 68%, 3g: 92%, 3h: 70%, 3i: 80%, 3j: 65% (yields over two steps).
rafts, tripartite structures with very efficient raftophilic membrane anchors should exhibit the highest potency. The tripartite structures 6a-j (Table 1 and 2) were synthesised using the membrane anchor building blocks 3a-j (Scheme 1), the peptidic inhibitor GL 189 and the 4Gl-3Gl-4Gl-3Gl-4Gl spacer module.
The spacer length was kept constant (approx. 89 Å, assuming an extended conformation of the spacer) to have results comparable with existing data. 26 The effect of 6a, 6c, 6d and 6j on the generation of sAPPβ by HeLa cells overexpressing the Swedishmutant form of human APP was studied before at two concentrations (20 and 200 nM) . 25 The tripartite structure 6a with the dihydrocholesteryl anchor was reported to be most potent. Compound 6j with a cis double bond in the oleyl anchor was found to be essentially inactive. Overall, the efficiency of different tripartite structures in BACE1 inhibition appeared to resemble their degree of raft partitioning. In our previous study, cells expressing Swedish-mutant or wild-type APP showed differences with respect to the BACE1 inhibiting activity of tripartite structures and the secretion of Aβ-peptides. 26 Therefore, we conducted an extensive comparative study of the activity of tripartite structures with a range of different membrane anchors (long-chain lipid alcohols ranging from C 14 -C 26 , dihydrocholesterol and cholesterol) in SH-SY5Y cells overexpressing wild-type APP. To compare the tripartite inhibitors on the basis of reliable EC 50 values, each compound was tested in serial dilutions in at least three independent experiments. In addition, for some compounds the range of tested concentrations was varied between different experiments to improve the accuracy of the determination of top and bottom plateaus of the dose-response curves. Consequently, not each single compound dilution depicted below was tested in all three experiments. The dose-response curves for tripartite compounds 6a-d, 6f and 6i are shown in Fig. 3 .
The tripartite structures 6a and 6b with cholesterol and dihydrocholesterol as raftophilic membrane anchors reduced very efficiently Aβ40 release into the cell culture medium. The EC 50 values of 0.39 (log EC 50 = −9.406 ± 0.182) and 0.74 nM (log EC 50 = −9.130 ± 0.035) calculated for 6a and 6b were substantially lower than those of the tripartite structures 6c-i with longchain lipid alcohols as membrane anchors (Table 2) . To evaluate the statistical significance of the observed differences, we compared the log EC 50 values by one-way ANOVA and Tukey's multiple comparison post-test. The difference in log EC 50 between 6a (dihydrocholesteryl anchor, Dhc) and 6b (cholesteryl anchor, Compounds 6a and 6b were tested at concentrations ranging from 10 pM to 100 nM in SH-SY5Y APPwt cells. 6c and 6i were tested at concentrations from 1 nM to 10 μM; 6d was tested with alternating concentration ranges (once: 100 pM to 1 μM; twice: 1 nM to 10 μM); 6f was tested at concentrations from 100 pM to 1 μM. The dose-response curves were generated by pooling normalised data (means and SD) from three independent experiments (ESI, Table S2 †). It should be noted that the concentration ranges were varied between experiments for some compounds. In cases where error bars are shown, they represent data from at least two independent experiments. 8218 | Org. Biomol. Chem., 2012, 10, 8216-8235 Chol) did not reach statistical significance. However, both were significantly lower than each single log EC 50 value obtained for 6c-6i (for pairwise comparison of different anchors, see ESI, Table S1 †). This result is explained by the different partitioning of sterol and lipid alcohol anchors between raft and non-raft phases. As dihydrocholesteryl anchors bind more efficiently to the raft phase, 25 the tripartite structures 6a and 6b should be available in higher concentrations at the subcellular site of amyloidogenic APP cleavage. Within the series of tripartite structures with lipid alcohol anchors, a chain length of 18 to 24 carbon atoms provided the best result. Compounds 6e-h were equally potent (Fig. 4) , whereas the log EC 50 of 6c (log EC 50 = −6.752 ± 0.266) with the shortest lipid chain (C 14 ) was significantly higher than all other log EC 50 values in this series ( p < 0.001; ESI, Table S1 †). Compared to compounds 6e-h, the potency appeared to decrease for 6d (log EC 50 = −7.609 ± 0.342) and 6i (log EC 50 = −7.631 ± 0.124) with chain lengths of 16 and 26 atoms, albeit statistical significance was not reached. It is assumed that the observed influence of the chain length within lipid alcohol anchors may reflect subtle differences in the distribution between raft and non-raft domains.
Variations of the spacer module
According to the original tripartite structure concept, 24 the length of the spacer linking the pharmacophore to the membrane anchor was expected to play a crucial role for the inhibitory activity. The optimum spacer should position the pharmacophore at a distance from the plasma membrane approximately matching that of the BACE1 active site (or that of the β-secretase cleavage site within APP) (Fig. 1) . Theoretical spacer lengths of our tripartite inhibitors have been estimated assuming an all-anti-conformation for the chain. Therefore, these lengths correspond to a maximal theoretical length irrespective of the actual conformation of the spacer. In a previous study, tripartite structures with theoretical spacer lengths ranging from 35 to 89 Å were shown to efficiently reduce cellular Aβ production (compound 6a with an 89 Å spacer displayed the lowest EC 50 value). 26 To extend our previous work and to investigate the influence of both, spacer length and chemical composition, we tested a series of tripartite structures with theoretical spacer lengths ranging from 26 to 96 Å. The subtle variations in length in this range were implemented by different combinations of the spacer building blocks 4a-c, thus providing eleven tripartite structures: 6a, 7b, 7d, 7e, 7g-i, 7l, 7n, 7o and 7q (Table 1 and 3) .
Spacers with different chemical entities were tested. Previously, different spacer lengths ranging from 35 to 123 Å were assembled by amide coupling of the ω-aminooligoethylene glycol carboxylic acids 4a and 4b. In compounds 7a, 7c, 7f, 7m and 7p one-block oligoethylene glycol units have been used as spacers. They derive from the ω-aminooligoethylene glycol carboxylic acids 4c-g containing 6, 8, 12, 16 and 24 oligoethylene glycol units and thus have no amide bonds within the spacer module. The phenylacetic acids 5a and 5b were used to construct a further type of spacer and led to the tripartite structures 7j and 7k with more lipophilic aromatic moieties in the spacer module (Fig. 2) .
In order to get data which are comparable to the previous ones, dihydrocholesterol was used as a lipid anchor and the peptidic transition state inhibitor GL189 as a pharmacophore. The tripartite structures 6a and 7a-q were shown to be highly active (Table 3) . Irrespective of the chemical composition of the spacer and the theoretical length (ranging from 26-96 Å), 6a and 7a-q exhibited EC 50 values below 7 nM. This finding indicates that within these limits the activities of our tripartite structures are relatively independent of the structure of the spacer module.
As shown in Fig. 5 , the log EC 50 values of the tripartite structures 6a and 7a-q did not show a single minimum. The compounds could be roughly divided into two groups with EC 50 Compound 6e was tested with alternating concentration ranges (once: 1 nM-10 μM; twice: 100 pM-1 μM); compounds 6f and 6h were tested at concentrations ranging from 100 pM to 1 μM in SH-SY5Y APPwt cells. Compound 6g was tested twice at nine different concentrations from 100 pM-1 μM, while in the third experiment, a reduced number of only six concentrations was tested, ranging from 3 nM to 1 μM. Dose-response curves were generated by pooling normalised data (means and SD) from three independent experiments. † values below and above 1 nM, respectively. Interestingly, the difference in potency does not seem to depend on the chemical composition of the spacer. Among the structures with one-block oligoethylene glycol spacers, the four compounds 7a, 7c, 7f and 7p exhibit EC 50 values < 1 nM (7a: EC 50 = 0.56 nM; log EC 50 = −9.248 ± 0.097; 7c: EC 50 = 0.43 nM; log EC 50 = −9.368 ± 0.228; 7f: EC 50 = 0.37 nM; log EC 50 = −9.436 ± 0.038; 7p: EC 50 = 0.79 nM; log EC 50 = −9.104 ± 0.113), whereas the value of compound 7m was much higher (EC 50 = 6.18 nM, log EC 50 = −8.209 ± 0.216). Spacer modules containing phenylacetic acid as in 7j and 7k did not affect the activity of the tripartite structures as compared to spacers consisting exclusively of oligoethylene glycol units with theoretical spacer lengths from 48 Å to 58 Å (7j: EC 50 = 0.45 nM; log EC 50 = −9.343 ± 0.080; 7k: EC 50 = 0.59 nM; log EC 50 = −9.229 ± 0.282) ( Table 3 ). For a statistical evaluation of the results, 6a was chosen as the reference. The mean log EC 50 values of each spacer variation were compared to the mean log EC 50 of 6a by one-way ANOVA followed by Dunnett's multiple comparison post-test. The mean log EC 50 values of the tripartite structures 7d (log EC 50 = −8.578 ± 0.327), 7e
(log EC 50 = −8.954 ± 0.318), 7m (log EC 50 = −8.209 ± 0.216), 7n (log EC 50 = −8.702 ± 0.252) and 7q (logEC 50 = −8.810 ± 0.055) were significantly different from that of 6a (log EC 50 = −9.406 ± 0.182).
Apparent minima of the EC 50 values were observed for tripartite structures with theoretical spacer lengths of 33 Å (7c: EC 50 = 0.43 nM; log EC 50 = −9.368 ± 0.228), 48 Å (7f: EC 50 = 0.37 nM; log EC 50 = −9.436 ± 0.038) and 89 Å (6a: EC 50 = 0.39 nM; log EC 50 = −9.406 ± 0.182). However, it should be noted that the subtle differences of activity of tripartite structures with EC 50 values <1 nM did not reach statistical significance. In summary, our results indicate that the relative potency of the tripartite structures with theoretical spacer lengths ranging from 26 to 96 Å did neither solely depend on the number of amide groups nor on the chemical composition of the spacers. Oligoethylene glycols can form helical structures in water, 28 and thus it does not seem likely that the spacer molecules adopt a fully extended conformation in a physiological environment. Interactions with the aqueous medium and with cell membrane-related components may influence the conformation of the spacer and thus affect the potency of the tripartite structure.
Variation of the BACE1 inhibitor
Membrane anchoring considerably increases the efficacy of the peptidic BACE1 inhibitor GL189 in cellular assays. [24] [25] [26] In the present study, the tripartite structure concept has been tested on four literature-known BACE1 inhibitors: 8, 12, 15 and 17 (Fig. 6) . [29] [30] [31] [32] The inhibitors were adapted for solid-phase peptide synthesis to enable the attachment of a spacer and a raftophile. Thus, the structures had to be modified by adding a carboxyl group which served as a coupling partner for the N-terminus of the spacer. The modified pharmacophores were synthesised following literature procedures. [29] [30] [31] [32] The additional carboxyl groups either derive from modified protected starting materials or from attachment of carboxyl group-bearing moieties at a later stage of c Half maximal effect (EC 50 ) of inhibition of Aβ40 secretion from treated cells relative to control (1% DMSO). The value given is the delogarithmised mean log EC 50 of three independent experiments, except for 6a, which was tested in eight independent experiments. All compounds were tested at concentrations from 10 pM to 100 nM, except for 7m, which was tested at alternating ranges (once: 10 pM-100 nM; twice: 100 pM-1 μM). Log EC 50 was determined by nonlinear regression from dose-response curves (ESI, Table S2 †).
d EC 50 values of compounds 6a, 7d, 7e and 7n were also reported in ref. 26 . Subtle differences are due to adjustments in the statistical analysis of the data allowing direct comparison (ESI, Table S2 †). Fig. 5 Dependency of the log EC 50 from the theoretical spacer length for tripartite structures with oligoethylene glycol spacers. Compounds 7b, 7d, 7e, 7g-7l, 7n, 7o and 7q with assembled spacers are depicted as blue dots. Compounds 7a, 7c, 7f, 7m and 7p with one-block spacers without internal amide bonds are depicted as red squares. To assess the statistical significance, the mean log EC 50 values were compared to that of compound 6a (green dot) by one way-ANOVA combined with Dunnett's multiple comparison post-test. The mean log EC 50 values of compounds 7d, 7e, 7m, 7n and 7q were significantly different from that of 6a (**p < 0.01; ***p < 0.001) and higher than −9 (EC 50 = 1 nM).
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The first small-molecule inhibitor examined was the lysine derivative 8 (Elan Pharmaceuticals/Pharmacia & Upjohn; Fig. 6) . 13, 29 A K i value of 5 nM was reported for that compound. Tripartite structure 9 was obtained by coupling of the free carboxylic acid 8 to the spacer-membrane anchor module (-4Gl-3Gl-4Gl-3Gl-4Gl-Asp(ODhc)-NH 2 ). The tripartite structure 9 was reported to be an active inhibitor of BACE1 in cell-based assays. 26 This finding could not be reproduced and our present study demonstrated that the previous result was caused by an impurity.
In a previous structure-activity study, the isobutyl group at the sulfonamide and the free carboxylic acid were found to be crucial for the inhibitory effect of 8. 29 Thus, the carboxylic acid group of compound 8 should not be functionalised. As a different coupling strategy might lead to active tripartite derivatives of 8, we decided to connect the inhibitor and the spacer either via modification of the p-toluenesulfonamide or by replacement of the Fmoc-protecting group by a phenylacetic acid derivative. Both analogues could still exhibit inhibitory activity based on the structure-activity study. 29 The building blocks 24 and 28 for the solid-phase peptide synthesis were prepared from H-Lys(Cbz)-OtBu (21) (Scheme 2). For the synthesis of compound 24 with the modified sulfonamide, amine 21 was reductively alkylated with isobutyraldehyde. The secondary amine was converted into the sulfonamide 22 using benzyl 2-(4-(chlorosulfonyl)phenyl)acetate, which was prepared from 4-iodophenylacetic acid via benzyl protection, copper-catalysed coupling with thiobenzoic acid 33 and subsequent oxidative chlorination with trichloroisocyanuric acid. 34 Deprotection of 22 by cleavage of the benzyl ester and the carbamate followed by Fmoc-protection of the amine 23 afforded building block 24. -4Gl-3Gl-4Gl-3Gl-4Gl-Asp(ODhc)-NH 2 . EC 50 : inhibitor concentration at which inhibition of Aβ40 secretion from treated cells was half-maximal compared to the control condition (1% DMSO). The value given is the delogarithmised mean log EC 50 of three independent experiments. Log EC 50 was determined by non-linear regression from dose-response curves (ESI †).
Reductive amination of compound 21 and subsequent reaction with 4-toluenesulfonyl chloride afforded the sulfonamide 25.
29
Deprotection of the primary amine led to compound 26, which on amidation with the acid 27 and cleavage of the benzyl ester provided building block 28. Acid 27 is accessible by chemoselective protection of 4-hydroxyphenylacetic acid (34) as benzyl ester, 35 reaction with tert-butyl bromoacetate and cleavage of the tert-butyl ester.
The free inhibitor 8 and the derived tripartite structures 9, 10 and 11 were all unable to inhibit the Aβ40-secretion from SH-SY5Y APPwt cells at concentrations of up to 100 nM (8) and 1 μM (9, 10 and 11), respectively.
As the second small-molecule inhibitor we have chosen the hydrazone 12 (The Genetics Company Inc., Switzerland; Fig. 6 ). 30 An IC 50 value of 14.4 μM for an in vitro assay and activity in a cell-based assay were reported. 30, 36 Since no information on structure-activity relations was available, this inhibitor was attached via the mono-substituted aromatic ring using a benzoic or phenylacetic acid moiety (Scheme 3). The synthesis of the building blocks 32 and 33 started from commercially available 4-hydrazinobenzoic acid (30) and 4-hydrazinophenylacetic acid (31), prepared by diazotation and reduction of 4-aminophenylacetic acid. 37 Acid-catalysed condensation of ketone 29 with the hydrazines 30 and 31 provided the building blocks 32 and 33 with no need for protecting group operations at the carboxylic acids. 38 The tripartite structures 13 and 14, as well as the inhibitors 32 and 33 were unable to reduce the Aβ40-secretion from SH-SY5Y APPwt cells at concentrations of up to 100 nM (Fig. 6) .
The third non-peptidic small-molecule inhibitor of BACE1 investigated in our present study was the 2-amino-3,4-dihydroquinazoline 15 (Johnson & Johnson; Fig. 6 ). 31 An X-ray analysis of a structurally related 2-amino-3,4-dihydroquinazoline bound to the active site of BACE1 showed that the primary amine interacts with the catalytic aspartates of BACE1. 31 A K i value of 30 nM was found for rac-15, which was also active in a cell-based assay. Attachment of this inhibitor to the tripartite structure was achieved by substitution of the phenoxy group at the 6-position of the 3,4-dihydroquinazoline 15 by a 4-hydroxyphenylacetic acid. The primary amine and the cyclohexyl moieties are important for the activity of 15 because they interact with the catalytically active aspartates or the S 1 and S 1 ′ pockets of BACE1, respectively. Therefore, these structural units were left untouched. Furthermore, the modified substituent at the 2-amino-3,4-dihydroquinazoline could easily be introduced at the beginning of the synthesis, keeping the remaining steps similar to the known procedure (Scheme 4). 31 4-Hydroxyphenylacetic acid (34) was converted to the tert-butyl ester 35 using an excess of tert-butyl acetoacetate. 39 Nucleophilic aromatic substitution by reaction of 5-fluoro-2-nitrobenzaldehyde with the phenol 35 provided the diaryl ether 36. Subsequent reductive amination with amine 37 afforded compound 38.
31 Reduction of 38 to the aniline 39 followed by cyclisation using cyanogen bromide provided the 2-amino-3,4-dihydroquinazoline 40. Cleavage of the tert-butyl ester led to the phenylacetic acid 41.
40
The tripartite structure 16 turned out to be a potent inhibitor of cellular Aβ release from SH-SY5Y APPwt cells. The EC 50 of 14.8 nM (log EC 50 = −7.831 ± 0.057) for 16 as compared to 5.4 μM (log EC 50 = −5.266 ± 0.060) for the pharmacophore 41 indicated a substantial improvement of potency (Fig. 7) . A significant statistical difference for the mean log EC 50 values of 16 and 41 was revealed by Student's t-test ( p < 0.0001). This result showed that membrane targeting of a non-peptidic compound, which is only weakly active in a cellular assay, leads to a significant increase of the inhibitory activity.
As the fourth small-molecule BACE1 inhibitor we tested the spiropiperidine iminohydantoin 17 which was identified by high-throughput screening (Merck; Fig. 6 ). 32 An IC 50 value of 2.8 μM on the isolated enzyme and an activity in a cellular assay at 8.2 μM have been reported. 32 The cyclohexyl and fluorophenyl rings of 17 were found to be essential for high potency in vitro and good activity in the cell-based assay, respectively. Therefore, attachment to the spacer was achieved by modification of the substituent at the piperidine nitrogen. The spiropiperidine 42 is readily available via an Ugi reaction (Scheme 5). 32 In a first attempt the piperidine nitrogen of 42 was directly acylated with Fmoc-Glu-OtBu (43) . Subsequent acidic cleavage of the tertbutyl ester afforded building block 44. For the two pharmacophores 50 and 51, attachment to the spacer was projected by substitution of the 4-acetamido group of 17 with a glutamic or glutaric acid linkage, respectively. Thus, the structure of the pharmacophores was kept similar to the one reported in the literature. Protection of 4-nitrobenzyl alcohol by reaction with tertbutylchlorodimethylsilane, reduction to the aniline, 41 amidation with either Fmoc-Glu-OtBu (43) or mono-tert-butyl glutarate, 42 removal of the silyl protecting group and oxidation with manganese dioxide 43, 44 afforded the benzaldehydes 45 and 46. Reductive amination of the spiropiperidine 42 with the benzaldehydes 45 and 46 and subsequent cleavage of the tert-butyl ester led to compound 49 and the pharmacophore 50. Cleavage of the Fmoc group in 49 provided the glutamic acid-derived pharmacophore 51.
The tripartite structures 19 and 20 exhibited potent inhibition of Aβ40-secretion in a cellular assay with EC 50 values of 50.1 nM (log EC 50 = −7.300 ± 0.163) and 9.7 nM (log EC 50 = −8.014 ± 0.048) (Fig. 6 ), whereas the reference substances 17, 50 and 51 showed considerably higher EC 50 values of 0.863 μM (log EC 50 = −6.064 ± 0.178), 17.5 μM (log EC 50 = −4.758 ± 0.212) and 4.3 μM (log EC 50 = −5.368 ± 0.150), respectively (Scheme 5; ESI, Table S2 †). The tripartite structure 18 failed to inhibit BACE1 at concentrations up to 10 μM. Pairwise comparison of the log EC 50 values for the tripartite structures 19 and 20 and the free pharmacophores 17, 50 and 51 by one-way ANOVA and Tukey's post-test showed that all five differed significantly from each other (ESI, Fig. S1 and Table S3 †). In contrast to 18, the tripartite structures 19 and 20, which resemble structure 17 Aβ40 concentrations in cell culture supernatants are expressed as percent of the control condition C (1% DMSO). The curves were generated by non-linear regression on pooled normalised data from three independent experiments. Compound 16 was tested in alternating concentration ranges in SH-SY5Y APPwt cells (once: 30 pM-100 nM, 1 μM; twice: 300 pM-3 μM). Compound 41 was tested in two experiments at nine different concentrations ranging from 10 nM to 100 μM and for confirmation, in a third experiment at a reduced number of concentrations (10 nM, 100 nM, 1 μM, 10 μM, 100 μM). (B) Log EC 50 values of tripartite structure 16 and pharmacophore 41 from three independent experiments were compared by an unpaired, two-tailed t-test. Mean log EC 50 values were significantly different (***p < 0.0001). The lines and error bars represent means and standard deviations from three independent experiments. more closely, were highly active. The potency of 20, the most active tripartite structure within this series, exceeded that of inhibitor 17 by almost two orders of magnitude. This outcome emphasises that the potency of intrinsically cell-permeable BACE1 inhibitors can be enhanced considerably by membrane anchoring. The tripartite structure 20 is significantly more active than 19, which differs from the former only by the presence of an amino group in the linkage to the pharmacophore. Obviously, decreased polarity in the region of the hydrophobic S 3 binding pocket results in increased activity.
Conclusions
The present results provide strong evidence for our tripartite structure concept. 24 We have demonstrated that the cellular activity of small-molecule BACE1 inhibitors can be significantly increased by membrane targeting via a spacer with a raftophilic membrane anchor. A careful selection of the coupling strategy is crucial to avoid alteration of essential pharmacophoric groups of the inhibitor which may lead to a loss of inhibitory activity. The tripartite structure concept leads to an enrichment of the membrane-bound inhibitor in the lipid rafts which may reduce unwanted off-target side effects caused by the free BACE1 inhibitor. The ability of the membrane anchor to bind to lipid rafts strongly depends on its structure. This raftophilicity determines the concentration of the tripartite structure at the site of APP cleavage and therefore the potency of our compounds. Our observations indicate that a variation of the theoretical linker length from 26 to 96 Å has only a small impact on the inhibitory activity of the tripartite structure. This observation is tentatively explained by a spacer conformation which is not fully elongated in an aqueous environment. It is a further advantage of our concept that tripartite structures are relatively tolerant to structural changes in the spacer.
Experimental General
The spacer building blocks 4a and 4b, and Fmoc-statine were purchased from Polypeptide, France. The spacer building blocks 4c-g were purchased from Iris Biotech, Germany. The other amino acids and activation agents were bought from Novabiochem/Merck. All reactions were carried out using dry solvents in oven-dried glassware under an argon atmosphere. Solvents were dried using a solvent purification system (MBraun-SPS). Other chemicals were used as received from commercial sources. Flash chromatography was carried out using silica gel from Acros Organics (0.035-0.070 mm) and a Sepacore system (Büchi). The tripartite structures were assembled by automated solid-phase peptide synthesis on an ABI 433A peptide synthesiser with a UV detector (Fmoc-strategy, PAL-PEG-PS resin, HATU or HBTU activation). ATR FT-IR spectra were recorded on a Thermo Nicolet Avatar 360. NMR spectra were recorded on a Bruker Avance II 300, on a Bruker DRX 500 and an Avance III 600; δ in ppm with the non-deuterated solvent as an internal standard, 45 J in Hz. Mass spectra were measured on a Bruker Esquire LC Electrospray MS. The most abundant mass is given as theoretical mass. HRMS was measured on an LTQ ORBI-TRAP XL instrument (ThermoScientific) with a resolution of 60 000 and a mass accuracy within 3 ppm. Analytical HPLC was carried out on an Agilent Model 1100 with G1315B UV-DAD (detection at 215, 260 and 560 nm), G1321A fluorescence and an evaporative light scattering detector (ELS 1000, Polymer Laboratories). Column: Vydac 208TP104 (reversephase C 8 , 4.6 × 250 mm). 
Fmoc-Asp(O-C 14 H 29 )-OH (3c).
A solution of Fmoc-AspOtBu (1) (5.56 g, 13.5 mmol), MSNT (4.00 g, 13.5 mmol) and MeIm (1.11 g, 13.5 mmol) in CH 2 Cl 2 (60 mL) was stirred for 10 min and myristyl alcohol (2.63 g, 12.3 mmol) was added subsequently. After stirring for 4 h at room temperature, the mixture was partitioned between 2% aqueous citric acid and CH 2 Cl 2 , washed with 2% citric acid, H 2 O and brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was purified by flash chromatography (SiO 2 ; petroleum ether/diethyl ether, 2 : 1), affording the protected ester as a colourless solid, yield: 5.56 g (76%). This product (5.00 g, 8.23 mmol) was dissolved in CH 2 Cl 2 (15 mL). CF 3 COOH (10 mL) was added at 0°C, the mixture stirred at room temperature for 90 min, diluted with CH 2 Cl 2 and washed four times with water and once with brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was purified by flash chromatography (SiO 2 ; petroleum ether/diethyl ether [2 : 1] + 0.5% AcOH), affording 3c as a colourless solid, yield: 2 Cl 2 (20 mL) was stirred for 10 min and stearyl alcohol (301 mg, 1.11 mmol) was added subsequently. After stirring for 14 h at room temperature, the mixture was partitioned between 2% aqueous citric acid and CH 2 Cl 2 , washed with 2% citric acid, H 2 O and brine. The organic layer was dried over Na 2 SO 4 and evaporated to yield a colourless viscous oil, which was dissolved in CH 2 Cl 2 (5 mL). After addition of CF 3 COOH (6.25 mL) at 0°C, the mixture was stirred at room temperature for 90 min, diluted with CH 2 Cl 2 and washed four times with water and once with brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was 
Fmoc-Asp(O-C 24 H 49 )-OH (3h).
A solution of Fmoc-AspOtBu (1) (0.127 g, 0.314 mmol), MSNT (91.8 mg, 0.31 mmol) and MeIm (25.3 mg, 0.312 mmol) in CH 2 Cl 2 (25 mL) was stirred for 10 min and lignoceryl alcohol (0.100 g, 0.284 mmol) was added subsequently. After stirring for 24 h at room temperature, the mixture was partitioned between 2% aqueous citric acid and CH 2 Cl 2 , washed with 2% citric acid, H 2 O and brine. The organic layer was dried over Na 2 SO 4 and evaporated to yield a colourless solid, which was dissolved in CH 2 Cl 2 (5 mL). CF 3 COOH (6.25 mL) was added at 0°C, the mixture stirred at room temperature for 90 min, diluted with CH 2 Cl 2 and washed four times with water and once with brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was purified by flash chromatography (SiO 2 
Fmoc-Asp(O-Oleyl)-OH (3j).
A solution of Fmoc-Asp-OtBu (1) (5.43 g, 13.2 mmol), MSNT (3.91 g, 13.2 mmol) and MeIm (1.08 g, 13.2 mmol) in CH 2 Cl 2 (15 mL) was stirred for 10 min and oleyl alcohol (2.50 g, 12.0 mmol) was added subsequently. After stirring for 4 h at room temperature, the mixture was partitioned between 2% aqueous citric acid and CH 2 Cl 2 , washed with 2% citric acid, H 2 O and brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was purified by flash chromatography (SiO 2 ; petroleum ether/diethyl ether, 2 : 1), affording the protected ester as a colourless solid, yield: 6.20 g (78%). This product (6.00 g, 9.07 mmol) was dissolved in CH 2 Cl 2 (25 mL). CF 3 COOH (15 mL) was added at 0°C, the mixture stirred at room temperature for 90 min, diluted with CH 2 Cl 2 and washed four times with water and once with brine. After drying over Na 2 SO 4 and removal of the solvent, the residue was purified by flash chromatography (SiO 2 ; petroleum ether/diethyl ether 2 (64 μL, 0.37 mmol) in methanol (4 mL), and finally isobutyraldehyde (58 μL, 0.64 mmol) were added one after the other to a solution of NaBH 3 CN (40.3 mg, 0.642 mmol) in methanol (10 mL). The mixture was stirred at room temperature for 2 h. The major part of methanol was removed and the mixture was partitioned between ethyl acetate and K 2 CO 3 (halfsat. aqueous). The organic layer was washed with brine and dried over Na 2 , 3 H), 1.29 (s, 9 H), 1.44-1.62 (m, 5 H), 1.85-1.99 (m,  2 H 3398, 2952, 2872, 1727, 1710, 1686, 1653, 1617, 1596, 1558,  1528, 1456, 1395, 1367, 1336, 1308, 1244, 1230, 1147, 1111 ν = 3304, 2931, 2864, 1726, 1674, 1595, 1537, 1512 Benzyl 4-(2-tert-butoxy-2-oxoethoxy)phenylacetate. tert-Butyl bromoacetate (4.00 mL, 27.1 mmol) was added dropwise to a mixture of benzyl 4-hydroxyphenylacetate (6.57 g, 27.1 mmol) and Cs 2 CO 3 (13.3 g, 40.7 mmol) in DMF (60 mL). The reaction mixture was stirred at room temperature for 5 h. The reaction mixture was diluted with ethyl acetate and washed four times with water and once with brine. The organic layer was dried over Na 2 49 (s, 9 H), 3.61 (s, 2 H 32: A solution of 3,5-dichloro-2-hydroxyacetophenone (29) (1.00 g, 4.88 mmol) and 4-hydrazinobenzoic acid (30) (0.742 g, 4.88 mmol) in ethanol (90 mL) and AcOH (0.25 mL) was stirred at reflux for 2.5 h. During the reaction, brown crystals precipitated and were collected by filtration of the hot reaction mixture. The filtrate was concentrated, ethanol (30 mL) was added, the mixture was heated at reflux and filtered immediately. These steps were repeated (10 mL ethanol). After drying 32 was obtained as brown crystals, yield: 1.09 g (66%), m.p. Typical procedure for the preparation of the peptides H-Glu-Val-Asn-Sta-Val-Ala-Glu-Phe-4Gl-3Gl-4Gl-3Gl-4Gl-Asp-(ODhc)-NH 2 (6a), where Sta is (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid. Loading and automated assembly of Asp (ODhc) 14 to Glu 1 : the PAL-PEG-PS resin (0.38 mmol g −1 , 0.30 mmol) was subjected to automated deprotection, and loaded with Fmoc-Asp(ODhc)-OH, which was automatically activated and coupled. While the majority of the amino acids was coupled using the standard cycle as described above, the building blocks 4d-g, 24, 28, 32, 33, 41, 44, 49 and 50 were manually activated: the amino acid (2 equiv. based on the resin) was dissolved in DMF (2 mL). HATU (2 equiv. based on the resin) and EtN(i-Pr) 2 (2 equiv. based on the resin) were added and the mixture was stirred at room temperature for 10 min. Then EtN(i-Pr) 2 (2 equiv. based on the resin) was added and the mixture was transferred to the synthesiser, where coupling, washing and deprotection took place. Cleavage and postcleavage processing: after washing with CH 2 Cl 2 and drying in vacuo, the peptide was cleaved by stirring in CF 3 COOH/ (i-Pr) 3 
299-301°C. IR (ATR)
:
Cell culture
An SH-SY5Y cell line stably overexpressing wild-type APP695 with an N-terminal Myc tag and a C-terminal Flag tag 46 was kindly provided by L. Münter and G. Multhaup (Freie Universität Berlin). The cells were cultured in D-MEM/F12, supplemented with 10% fetal calf serum, 2 mM L-glutamine, nonessential amino acids and 50 μg mL −1 hygromycin B. Cultures were grown at 37°C, 5% CO 2 .
Inhibitor treatments
The test compounds were initially dissolved in DMSO at concentrations of 5 or 10 mM and stored in aliquots at −20°C. For the cell culture experiments, compound dilutions (100× of the desired final concentration in the test) were prepared in 100% DMSO, and were freshly diluted 1 : 100 with cell culture medium. The final concentration of DMSO in the experiments and controls was 1%. The culture medium in the cell culture plates was replaced with the fresh medium containing the compounds or 1% DMSO (blank test). For the ECL measurements SH-SY5Y cells were seeded 24 h before treatment in 96 well cell culture plates at a cell density of 2 × 10 5 cells cm −2 . The compounds were diluted in the medium and added to the cells as described above. For each condition six wells were used and pooled after an incubation time of 4-5 h.
Electrochemiluminescence (ECL) assay
Aβ-peptides in cell supernatants were measured with the MSD® Human (6E10) Abeta 40 Kit according to the manufacturer's protocol on a Sector™ Imager 6000 (Meso Scale Discovery). The synthetic reference peptide dilutions were prepared in 1% blocker A. The fetal calf serum present in the SH-SY5Y cell culture medium contains bovine Aβ-peptides which are detected by the ECL assay. The amount of the bovine Aβ40 in an unconditioned culture medium was determined to be ∼50 pg mL −1 , and this background value was subtracted from the calculated Aβ concentrations in the SH-SY5Y cell culture experiments.
Dose-response curves and EC 50 determinations
For the calculation of dose-response curves and EC 50 values for SH-SY5Y APPwt cells, all compounds were tested in three independent experiments in approximately half-logarithmic serial dilutions. For six compounds (6d, 6e, 7m, 16, 19 and 20) , ranges of inhibitor concentrations were altered in different experiments in order to define both top and bottom plateaus of the dose-response curve. Therefore, not each single concentration was analysed in all three experiments. Error bars in the corresponding graphs represent data from at least two experiments. For four other compounds (free pharmacophores 41, 17, 51 and anchor variant 6g), at least two experiments were conducted over the full concentration range (nine inhibitor dilutions and DMSO control), while in a third experiment a reduced number of concentrations was used to confirm the EC 50 . After 4-5 h incubation at 37°C and 5% CO 2 , the cell culture supernatants from 6 wells of a 96 well culture plate were pooled and measured in duplicate with the Aβ40 ECL assay. The signals were normalised to % of the DMSO controls. Means of the normalised duplicate values were plotted against inhibitor concentration and the log EC 50 values were calculated by non-linear regression using GraphPad Prism 5.01 software (GraphPad Software Inc., La Jolla, USA).
Statistical analysis
Statistical analysis was performed with the GraphPad Prism Software, version 5.01. The initial result obtained from curve fitting by non-linear regression is the log EC 50 of the compound (not the EC 50 , which is calculated in a second step). To compare the potency of different compounds, the respective log EC 50 values from at least 3 independent experiments were averaged and subjected to statistical tests. For two compounds, Student's t-test (two-tailed, unpaired) was used to compare means and variations of log EC 50 values, while a one-way ANOVA was employed for comparison of three or more compounds. In this case, either Dunnett's (comparison of all compounds to one reference compound) or Tukey's ( pairwise comparison of all compounds) post-test was added to correct for multiple testing. In our previous publication, 26 we pooled normalised values from three independent measurements to calculate the EC 50 by non-linear regression from the pooled dataset. This method leads to slightly different EC 50 values. In this study, pooled datasets were used only for the representation of dose-response curves in graphs, allowing a more clear visualisation. For all statistical analyses, log EC 50 means and standard deviations from three independent measurements were used, because this method facilitates comparison of multiple compounds. A comparison of log EC 50 and de-logarithmised EC 50 values calculated by averaging values from three or more experiments with EC 50 values obtained by non-linear regression analysis of pooled datasets revealed very small differences (ESI, Table S2 †).
